Papillary and follicular thyroid cancer, together referred to as differentiated thyroid cancer (DTC),
is … Instead, clinicians rely on large patient cohort studies in which therapy has not been …

… the limited role of radioiodine for dedifferentiated thyroid cancer, call for further efforts in
the … of targeted therapies in the approach of dedifferentiated papillary thyroid cancer (DePTC). …

… cancers) or primary thyroid lymphoma. Within the differentiated thyroid cancer family,
papillary thyroid cancer … with follicular thyroid cancer [3]. Analysis of 15,698 patients who had …

… Following 131 I therapy given only to ablate normal thyroid gland remnants, … thyroid hormone
therapy alone (P <0.001). No patient treated in this way with 131 I has died of thyroid cancer…

… with iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation
may be a predictor of the efficacy of iodine-131 treatment for papillary thyroid cancer. …

… , the incidence of thyroid cancer increased by 211% in the USA, driven mostly by the increase
of papillary thyroid cancer (PTC). With the high incidence of thyroid cancer, mortality rate …

… changes adopted recently by the American Thyroid Association (ATA). This … thyroid cancer.
The BRAF V600E mutation is the most common genetic alteration in papillary thyroid cancer (…

… Background: A limited number of targeted therapy options exist for papillary thyroid cancer
(PTC) to date. Based on genetic alterations reported by the “The Cancer Genome Atlas (TCGA…

… of papillary thyroid cancer employed in … papillary thyroid cancer during follow-up averaging
about a decade. However, in 84 persons (14.6 percent), of whom five eventually died, cancer …

… , chemotherapy. This continues to be an area of exciting research for emerging therapy, … or
re-establishing the differentiated features of the thyroid cancer cell, in an effort to optimize the …